<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02691013</url>
  </required_header>
  <id_info>
    <org_study_id>151294</org_study_id>
    <nct_id>NCT02691013</nct_id>
  </id_info>
  <brief_title>The Impact of Ramelteon on Sleep and Delirium in Patients Who Undergo Pulmonary Thromboendarterectomy (PTE) Surgery</brief_title>
  <official_title>The Impact of Ramelteon on Sleep and Delirium in Patients Who Undergo Pulmonary Thromboendarterectomy (PTE) Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sleep deprivation is known to affect brain function but is often ignored in the sickest
      patients including those in the intensive care unit after major surgery. In these patients,
      the levels of melatonin can also be altered. Melatonin is a hormone secreted in the brain
      that maintains the body's sleep-wake, or circadian, cycle. The investigators want to test
      whether improving sleep quality affects the risk of developing confusion (delirium) in
      patients having clot removed from their lung (open heart surgery). In order to improve sleep
      quality, the investigators will conduct a study of Ramelteon, a medication that mimics the
      activity of melatonin and measure its effects on levels of melatonin and monitor sleep.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Anticipated">December 30, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of Delirium</measure>
    <time_frame>Twice daily for up to 10 days</time_frame>
    <description>Measured twice daily during the ICU stay using the Confusions Assessment Method instrument.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Duration of Sleep</measure>
    <time_frame>Daily for up to 10 days</time_frame>
    <description>Participants wore an actigraphy device on their wrist for the duration of their ICU stay. This device continuously measures activity, and thus estimates sleep time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Delirium</measure>
    <time_frame>Twice daily for up to 10 days</time_frame>
    <description>Measured twice daily over the course of the ICU stay using the Confusion Assessment Method instrument</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Daily Critical Care Pain Observation Tool (CPOT)</measure>
    <time_frame>10 days</time_frame>
    <description>average daily pain level using the CPOT Participants can score from 0 to 6 on the CPOT scale, with 0 being no pain (calm, comfortable), and 6 representing significant pain/agitation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospital Stay</measure>
    <time_frame>Duration of hospital admission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU Stay</measure>
    <time_frame>Duration of hospital admission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of Light Quality in the Patient's Room</measure>
    <time_frame>3 days</time_frame>
    <description>Light meter placed at bedside in patient room; this meter measured and recorded the light level in lux for ever minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of the Sound Levels in the Patient's Room</measure>
    <time_frame>3 days</time_frame>
    <description>Sound meter was placed at bedside in each patient room. This meter measured and recorded the sound level in decibels every two seconds.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Delirium</condition>
  <condition>Sleep Deprivation</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive a Placebo tablet every evening.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ramelteon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive Ramelteon 8mg every evening.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramelteon</intervention_name>
    <arm_group_label>Ramelteon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH) who are admitted
             to UCSD for a planned PTE surgery.

          -  Age &gt; 18 years

        Exclusion Criteria:

          -  Pregnancy

          -  Cirrhosis of any etiology

          -  Current use of any atypical antipsychotic including Fluvoxamine (contra-indicated with
             Ramelteon)

          -  Any contraindication to EEG/Sleep recording

          -  Non-English speaking (who are unable to complete delirium questionnaires)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Owens</last_name>
    <role>Principal Investigator</role>
    <affiliation>8686577118</affiliation>
  </overall_official>
  <reference>
    <citation>Al-Aama T, Brymer C, Gutmanis I, Woolmore-Goodwin SM, Esbaugh J, Dasgupta M. Melatonin decreases delirium in elderly patients: a randomized, placebo-controlled trial. Int J Geriatr Psychiatry. 2011 Jul;26(7):687-94. doi: 10.1002/gps.2582. Epub 2010 Sep 15. Erratum in: Int J Geriatr Psychiatry. 2014 May;29(5):550.</citation>
    <PMID>20845391</PMID>
  </reference>
  <reference>
    <citation>Bellapart J, Boots R. Potential use of melatonin in sleep and delirium in the critically ill. Br J Anaesth. 2012 Apr;108(4):572-80. doi: 10.1093/bja/aes035. Review.</citation>
    <PMID>22419624</PMID>
  </reference>
  <reference>
    <citation>Hatta K, Kishi Y, Wada K, Takeuchi T, Odawara T, Usui C, Nakamura H; DELIRIA-J Group. Preventive effects of ramelteon on delirium: a randomized placebo-controlled trial. JAMA Psychiatry. 2014 Apr;71(4):397-403. doi: 10.1001/jamapsychiatry.2013.3320.</citation>
    <PMID>24554232</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>December 28, 2015</study_first_submitted>
  <study_first_submitted_qc>February 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2016</study_first_posted>
  <results_first_submitted>July 17, 2019</results_first_submitted>
  <results_first_submitted_qc>September 9, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 20, 2019</results_first_posted>
  <last_update_submitted>September 19, 2019</last_update_submitted>
  <last_update_submitted_qc>September 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Robert L. Owens</investigator_full_name>
    <investigator_title>Associate Professor, Pulmonary, Critical Care and Sleep Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
    <mesh_term>Sleep Deprivation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 23, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/13/NCT02691013/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Patients will receive a Placebo tablet every evening starting the night prior to the procedure for a maximum of 7 nights total.
Placebo</description>
        </group>
        <group group_id="P2">
          <title>Ramelteon</title>
          <description>Patients will receive Ramelteon 8mg every evening starting the night prior to the procedure for a maximum of 7 nights total.
Ramelteon</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>120 enrolled. 3 participants withdrew prior to receiving any drug. Reporting the results of the 117 who were analyzed.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Patients will receive a Placebo tablet every evening.
Placebo</description>
        </group>
        <group group_id="B2">
          <title>Ramelteon</title>
          <description>Patients will receive Ramelteon 8mg every evening.
Ramelteon</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="58"/>
            <count group_id="B2" value="59"/>
            <count group_id="B3" value="117"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="58"/>
                    <count group_id="B2" value="59"/>
                    <count group_id="B3" value="117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="58"/>
                    <count group_id="B2" value="59"/>
                    <count group_id="B3" value="117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.1" spread="15.8"/>
                    <measurement group_id="B2" value="58.1" spread="14.1"/>
                    <measurement group_id="B3" value="57.1" spread="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="58"/>
                    <count group_id="B2" value="59"/>
                    <count group_id="B3" value="117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="58"/>
                    <count group_id="B2" value="59"/>
                    <count group_id="B3" value="117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Duration of Delirium</title>
        <description>Measured twice daily during the ICU stay using the Confusions Assessment Method instrument.</description>
        <time_frame>Twice daily for up to 10 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients will receive a Placebo tablet every evening starting the night prior to the procedure for a maximum of 7 nights total.
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Ramelteon</title>
            <description>Patients will receive Ramelteon 8mg every evening starting the night prior to the procedure for a maximum of 7 nights total.
Ramelteon</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Delirium</title>
          <description>Measured twice daily during the ICU stay using the Confusions Assessment Method instrument.</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="10" upper_limit="29"/>
                    <measurement group_id="O2" value="24" lower_limit="14" upper_limit="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Duration of Sleep</title>
        <description>Participants wore an actigraphy device on their wrist for the duration of their ICU stay. This device continuously measures activity, and thus estimates sleep time.</description>
        <time_frame>Daily for up to 10 days</time_frame>
        <population>Due to funding &amp; logistical constraints, only a subset of subjects would've been able to do the electroencephalography (EEG) monitoring used for sleep assessment. Thus, Total Duration of Sleep was not measured and we focused on our a priori secondary outcome of incident delirium, a change made before the start of data collection or analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients will receive a Placebo tablet every evening.
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Ramelteon</title>
            <description>Patients will receive Ramelteon 8mg every evening.
Ramelteon</description>
          </group>
        </group_list>
        <measure>
          <title>Total Duration of Sleep</title>
          <description>Participants wore an actigraphy device on their wrist for the duration of their ICU stay. This device continuously measures activity, and thus estimates sleep time.</description>
          <population>Due to funding &amp; logistical constraints, only a subset of subjects would've been able to do the electroencephalography (EEG) monitoring used for sleep assessment. Thus, Total Duration of Sleep was not measured and we focused on our a priori secondary outcome of incident delirium, a change made before the start of data collection or analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Delirium</title>
        <description>Measured twice daily over the course of the ICU stay using the Confusion Assessment Method instrument</description>
        <time_frame>Twice daily for up to 10 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients will receive a Placebo tablet every evening starting the night prior to the procedure for a maximum of 7 nights total.
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Ramelteon</title>
            <description>Patients will receive Ramelteon 8mg every evening starting the night prior to the procedure for a maximum of 7 nights total.
Ramelteon</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Delirium</title>
          <description>Measured twice daily over the course of the ICU stay using the Confusion Assessment Method instrument</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Daily Critical Care Pain Observation Tool (CPOT)</title>
        <description>average daily pain level using the CPOT Participants can score from 0 to 6 on the CPOT scale, with 0 being no pain (calm, comfortable), and 6 representing significant pain/agitation.</description>
        <time_frame>10 days</time_frame>
        <posting_date>12/2019</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Hospital Stay</title>
        <time_frame>Duration of hospital admission</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients will receive a Placebo tablet every evening starting the night prior to the procedure for a maximum of 7 nights total.
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Ramelteon</title>
            <description>Patients will receive Ramelteon 8mg every evening starting the night prior to the procedure for a maximum of 7 nights total.
Ramelteon</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Hospital Stay</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="10" upper_limit="14"/>
                    <measurement group_id="O2" value="12" lower_limit="10" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of ICU Stay</title>
        <time_frame>Duration of hospital admission</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients will receive a Placebo tablet every evening starting the night prior to the procedure for a maximum of 7 nights total.
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Ramelteon</title>
            <description>Patients will receive Ramelteon 8mg every evening starting the night prior to the procedure for a maximum of 7 nights total.
Ramelteon</description>
          </group>
        </group_list>
        <measure>
          <title>Length of ICU Stay</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="3" upper_limit="5"/>
                    <measurement group_id="O2" value="4" lower_limit="3" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measures of Light Quality in the Patient's Room</title>
        <description>Light meter placed at bedside in patient room; this meter measured and recorded the light level in lux for ever minutes.</description>
        <time_frame>3 days</time_frame>
        <posting_date>12/2019</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measures of the Sound Levels in the Patient's Room</title>
        <description>Sound meter was placed at bedside in each patient room. This meter measured and recorded the sound level in decibels every two seconds.</description>
        <time_frame>3 days</time_frame>
        <posting_date>12/2019</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Patients will receive a Placebo tablet every evening starting the night prior to the procedure for a maximum of 7 nights total.
Placebo</description>
        </group>
        <group group_id="E2">
          <title>Ramelteon</title>
          <description>Patients will receive Ramelteon 8mg every evening starting the night prior to the procedure for a maximum of 7 nights total.
Ramelteon</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Robert Owens</name_or_title>
      <organization>University of California San Diego</organization>
      <phone>858-657-5258</phone>
      <email>rowens@ucsd.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

